Moderna
MRNA
$132.64
Share price
2.77%
Change (1 day)
1.83%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.
Moderna (MRNA) - P/B ratio
P/B ratio as of May 2024 : 3.86
According to Moderna
's latest financial reports the company has a price-to-book ratio of 3.86.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Moderna - P/B ratio (from 2018 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 2.74 | -24.15% |
| 2022-12-31 | 3.61 | -50.43% |
| 2021-12-31 | 7.28 | -54.9% |
| 2020-12-31 | 16.1 | 188.09% |
| 2019-12-31 | 5.60 | 70.78% |
| 2018-12-31 | 3.28 | |
| 2017-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.25 | 35.98% | 🇺🇸 USA |
 Novartis NVS | 5.30 | 37.28% | 🇨🇭 Switzerland |
 Merck MRK | 8.87 | 129.73% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | 6.24 | 61.74% | 🇺🇸 USA |
 Athersys ATHX | -0.0229 | -100.59% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -85.0 | -2,303.44% | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | 17.9 | 363.92% | 🇺🇸 USA |